CareVet Launches Clinical Advisory Board to Advance Evidence-Based Veterinary Medicine
Comprised of forward-thinking experts with interests in dermatology, oncology, urgent care, orthopedic surgery, wellness, and internal medicine, the Clinical Advisory Board is committed to solving complex problems, trialing new medical treatments, and leveraging the latest advancements in AI and technology to enhance patient care. By sharing breakthroughs and developing best practices, the board plays a crucial role in shaping the future of veterinary medicine.
"ClinicalConnect, our internal exchange platform for the Board to share updates, is a game-changer—it helps us share real-life practice pearls, and stay connected across the CareVet network. It's a great tool for my team, and ultimately better for our patients," said Dr.
"The involvement of the CareVet Clinical Advisory Board, composed of experienced veterinarians and technicians, further enriches CareVet's network by offering insights and expertise," said Dr.
Through evidence-based decision-making, the Clinical Advisory Board will provide timely insights, pilot new treatments, and ensure that CareVet hospitals remain at the forefront of veterinary excellence. This initiative underscores CareVet's mission to improve clinical outcomes by applying the latest research and technological advancements to everyday practice.
For more information about the Clinical Advisory Board and CareVet's commitment to advancing veterinary medicine, visit carevethealth.com.
About CareVet
CareVet is a leading operator of veterinary hospitals across 35+ states with more than 2,500 Team Members. Founded in 2018 by Dr.
Media Contact:
View original content to download multimedia:https://www.prnewswire.com/news-releases/carevet-launches-clinical-advisory-board-to-advance-evidence-based-veterinary-medicine-302420787.html
SOURCE CareVet
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FIGHT FOR CONTROL OF PROFITABLE WEST VIRGINIA POWER PLANT ESCALATES WITH MOTION TO DISMISS BANKRUPTCY
- Personal Injury Case Insights Explained in HelloNation Featuring Personal Injury Attorney Joe Stanley
- InnoCare Announces Approval of Head-to-Head Registrational Phase III Trial of Mesutoclax with Azacitidine versus Venetoclax with Azacitidine in Treatment-Naive AML in China
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share